A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentations have concluded.

Welcome to the CytomX Therapeutics fourth-quarter 2024 and financial results call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host for today, ...

CX-2051 contains a next generation topoisomerase-1 payload (CAMP59) and a cleavable payload-antibody linker licensed from AbbVie (formerly Immunogen). EpCAM (Epithelial Cell Adhesion Molecule ...

Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 ...

Antibody fragments have also been developed ... Six targets for multiple fragments (CD20, CD22, carcinoembryonic antigen (CEA), EpCAM, HER2/Neu and Lewis Y) are also common targets for full ...

EpCAM (also called HEA or BerEP4 ... hinders our ability to capture CTCs with high efficiency. The addition of antibodies targeting mesenchymal markers may help in alleviating this problem.

Data were summarized with the search of 'colorectal' and 'antibody' as of August 2012 at ClinicalTrials.gov [202]. EGFR: EGF receptor; mAb: Monoclonal antibody; VEGFR: VEGF receptor. The authors ...

The strong evidence, though that EpCAM targeting with locally delivered approaches can achieve clinical anticancer activity, including the multi-specific antibody, Korjuny, that is currently being ...

Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX ...